BIO-TECH SYSTEMS, INC., founded in 1980, specializes in market research and strategic planning, where technological and scientific insight is important. This focuses on emerging technologies where it is necessary to make accurate forecasts of future market demand and communicate effectively with many levels of management and end-users. One objective is to assess technological risk and target new products and services effectively in order to generate the best market response. Bio-Tech has an extensive group of clients with interests in medical imaging, radiopharmaceuticals and radiotherapy products.
Bio-Tech focuses in five product areas with comprehensive reports that analyze market opportunities in each segment. The product areas include Diagnostic and Therapeutic Radiopharmaceuticals, PET radiopharmaceuticals and PET imaging, Medical Imaging Contrast Media, Radiotherapy and Immunotherapy products, and Brachytherapy products.
The methodology utilized has been developed over 20 years in this field focusing on both researchers and clinicians in these fields as well as knowledgeable industry sources. This provides insight with respect to market trends as well as new technology entering the pipeline. Bio Tech also benefits from its large internal database that is regularly updated. As a result, the company’s forecasts are both conservative and realistic and can be used with confidence in market planning and evaluation of new business opportunities.
The company's founder, Marvin Burns, has been active in the medical industry and hospital community for over 20 years and has prepared numerous market research reports that have been widely distributed. The reports have served as a platform for assessing new ventures and business opportunities across a broad spectrum of products. Burns has also served as a consultant to many of the major pharmaceutical and medical imaging companies and venture groups in evaluating new product and market opportunities.
BIO-TECH SYSTEMS has recently released the following market research reports. Click the links below to jump down and learn more.
Report #340: THE MARKET FOR PET RADIOPHARMACEUTICALS & PET IMAGING analyzes the dynamic market for PET radiopharmaceuticals and high performance PET scanners. International market growth has been particularly encouraging as the technology becomes more widely available and distribution of FDG improves. PET MR was successfully introduced in 2010 with good response, creating a new platform for PET. Recent sales growth has raised expectations of manufacturers and encouraged investment in new products and technology. New PET radiopharmaceuticals are also on the threshold for imaging Alzheimer's which will help in evaluating new drug candidates for treating the disease New PET perfusion agents for cardiology should also emerge in 2012 based on encouraging clinical data. New PET products for oncology also show promise of expanding PET’s role in treating and managing many prevalent cancers. Therefore, the demand for PET should continue to increase creating a solid platform for future growth.
Report #330: THE U.S. MARKET FOR SPECT AND PET RADIOPHARMACEUTICALS provides a comprehensive analysis of the markets for SPECT and PET radiopharmaceuticals. This covers nuclear cardiology, targeted oncology and new molecular imaging products for both PET and SPECT. It also analyzes the large emerging markets for imaging Alzheimer's and Parkinson's disease. New PET perfusion agents for cardiology will offer capabilities for diagnosing complex cases and encourage more physicians to adopt PET. Growth is also expected in cardiology SPECT from new products that are emerging. New molecular imaging modalities are being developed based on apoptosis, angiogenesis and cellular proliferation. Other agents are in the pipeline for imaging slow growing tumors not easily visualized with current PET or SPECT agents. These molecular imaging platforms will also have therapeutic applications, increasing their versatility and usefulness. This will encourage more investment from biopharmaceutical companies and venture groups that will enhance future market growth.
Report #290: THE U.S. MARKET FOR BRACHYTHERAPY PRODUCTS provides a comprehensive analysis of the markets for brachytherapy products. The report discuss the prospects for prostate seed implants and the effect of competing modalities, the rapidly growing market for partial breast irradiation devices and gynecological brachytherapy, new markets for electronic brachytherapy using miniaturized x-ray technology, sales growth for irradiated microspheres for liver cancer and the large emerging brachytherapy market for treating macular degeneration. The report also examines the continuing prospects for endovascular brachytherapy, the market for brain cancer brachytherapy and other post-surgical applications amenable to brachytherapy. The report considers the trade-offs between LDR (low dose rate) and HDR (high dose rate) brachytherapy, the integration of brachytherapy with other treatment modalities and the increasing number of options available to both clinicians and patients as new technology enters the mainstream. Many new brachytherapy products have been introduced recently with rapid growth in procedure volume. There are also new products on the threshold, with introduction scheduled in the near future. This will stimulate further growth and encourage wider acceptance of brachytherapy with improved outcomes for many patients.
Report #260: THE U.S. MARKET FOR MEDICAL IMAGING CONTRAST MEDIA provides a comprehensive analysis of the markets for medical imaging contrast media in all modalities including X-ray, CT, MRI and ultrasound. Noninvasive vascular imaging will increase dramatically, replacing traditional angiography in many cases. New molecular imaging and therapeutic modalities are also being developed based on apoptosis, angiogenesis and imaging of growth receptors that are expressed in a large number of cancers. This will bring imaging modalities such as MRI, CT, PET and ultrasound closer together, increasing the sensitivity and specificity of diagnoses. Ultrasound contrast procedures will also become more productive, since clinicians and sonographers have implemented protocols that are simpler and more effective to use. There is also excellent likelihood that the approved indications for ultrasound contrast agents will be extended to perfusion imaging in the future. This technical influx will help all segments of the contrast media field and will stimulate more research and investment, adding strength and stability to newer venture companies as well as those more established in the field.
Report #230: THE WORLD MARKET FOR THERAPEUTIC RADIOPHARMACEUTICALS analyzes the markets for therapeutic radiopharmaceuticals including current and emerging applications for lymphoma, colon cancer, lung cancer, prostate cancer, breast cancer, endocrine cancer and other cancers resistant to traditional therapies. There has been a surge in research activity to expand applications for therapeutic radiopharmaceuticals employing more sophisticated targeting methodologies and more appropriate therapeutic isotopes for the tumors being treated. This has prompted increased interest in alpha emitters, where the shorter particle range and high-energy deposition can be used to advantage to destroy DNA directly, minimizing toxicity and protecting neighboring healthy cells. The growing use of molecular imaging is also helping to control and monitor dosage for increased safety and effectiveness. As these products enter the mainstream, there will be others in the pipeline for treating a variety of cancers. This will stimulate investment with greater support from large pharmaceutical companies. One motivator is the potential return on investment and the high price of these products, which is justified by their unique capabilities.
Marvin Burns is president of BIO-TECH SYSTEMS, Inc., founded in 1980 to perform market research for companies in the healthcare field. Burns specializes in market evaluation, where technological and scientific insight is important. The company has prepared numerous market research reports on diagnostic and therapeutic radiopharmaceuticals, radiotherapy and immunotherapy products, brachytherapy, PET imaging, contrast agents, and interventional cardiology, which have been widely distributed. Burns has served as a consultant to many international firms and venture groups in strategic planning and development of new business opportunities. He has also been Technology Editor of Future Oncology, a publication widely circulated in the pharmaceutical and biotechnology industry, reporting on new developments in cancer diagnosis and treatment. Burns is a graduate of MIT and Harvard Business School’s advanced management program. He has over 100 publications and 15 patents and invention disclosures. Prior to forming BIO-TECH SYSTEMS, he was employed by firms in life sciences, bioinstrumentation and medical imaging fields in general management, marketing and product development. He was also a hospital administrator in charge of professional and technical services including medical imaging, clinical laboratories, therapy services, and materials management.
mburns_cv.doc
-OR-
mburns_cv.pdf
Back to Top
Send
this page to a friend